DTP3 is primarily used in research settings for its potential in cancer therapy, particularly in targeting drug-resistant tumors. It functions by disrupting specific protein-protein interactions involved in cell survival pathways, making it a promising candidate for inducing apoptosis in malignant cells. Its application is especially notable in studies focused on overcoming resistance in p53-mutated cancers, where conventional treatments often fail. Due to its selective mechanism, DTP3 is being explored as a basis for developing more effective and targeted anti-cancer drugs with fewer side effects.